Wednesday, 26 December 2007

SIGMA Pharma agreed to buy Orphan Australia for $130 million

Sigma said Melbourne-based Orphan would provide it with an entry into a number of high-value, high-growth specialised therapeutics from international pharmaceutical and biotechnology companies, which Orphan focuses on licensing, marketing and distributing. With double-digit revenue growth in each of the past three years, Orphan is expected to generate sales of around $40 million and earnings before interest, taxation depreciation and amortisation of around $13 million during the year to June 2008, a Sigma statement said.

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker